GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) touted data today from a non-inferiority lung function study evaluating its inhaled, once-daily corticosteroid/long-acting beta2 agonist combination therapy in patients with asthma.
The study showed that patients with well-controlled asthma could switch from the twice-daily Seretide Accuhaler to the companies’ once-daily Relvar Ellipta therapy without compromising lung function.
Get the full story at our sister site, Drug Delivery Business News.
The post GlaxoSmithKline, Innoviva tout data for Relvar Ellipta inhaled drug combo appeared first on MassDevice.